Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 464 articles:
HTML format
Text format



Single Articles


    May 2018
  1. PLEYER C, Wiestner A, Sun C
    Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 May 15:1-9. doi: 10.1080/10428194.2018.1457147.
    PubMed     Text format     Abstract available


  2. YOGARAJAH M, Montgomery N, Matson M, Blanchard L, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Leuk Lymphoma. 2018 May 11:1-3. doi: 10.1080/10428194.2018.1459614.
    PubMed     Text format    


  3. OHANIAN M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, et al
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158.
    PubMed     Text format     Abstract available


  4. KRULL K, Kunstreich M, Bronsema A, Bleckmann K, et al
    Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
    Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292.
    PubMed     Text format     Abstract available


  5. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


    April 2018
  6. STAHL M, Pine A, Hendrickson JE, Litzow MR, et al
    Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey().
    Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219.
    PubMed     Text format    


  7. TAKEI T, Yokoyama K, Shimizu E, Konuma T, et al
    Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.
    Leuk Lymphoma. 2018 Apr 12:1-2. doi: 10.1080/10428194.2018.1443335.
    PubMed     Text format    


  8. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Text format     Abstract available


  9. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed     Text format    


  10. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed     Text format    


  11. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed     Text format    


  12. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed     Text format    


  13. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


  14. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Text format     Abstract available


    March 2018
  15. HOVERSTEN K, Vallapureddy R, Lasho T, Finke C, et al
    Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.
    Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212.
    PubMed     Text format    


  16. MACDONALD RJ, Bunaciu RP, Ip V, Dai D, et al
    Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452213.
    PubMed     Text format     Abstract available


  17. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


    February 2018
  18. JIANG JG, Xu Y, Wu Z, Ni H, et al
    Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma. 2018 Feb 23:1-3. doi: 10.1080/10428194.2018.1436174.
    PubMed     Text format    


  19. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed     Text format    


  20. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  21. MOLICA S, Levato L, Mirabelli R, Tedeschi A, et al
    Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436175.
    PubMed     Text format    


  22. ROZOVSKI U, Harris DM, Li P, Liu Z, et al
    Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167.
    PubMed     Text format     Abstract available


  23. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Text format     Abstract available


  24. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed     Text format    


  25. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Text format     Abstract available


  26. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed     Text format    


  27. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed     Text format    


  28. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Text format     Abstract available


  29. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed     Text format    


  30. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed     Text format    


  31. HE F, Sapkota S, Parker S, Defor T, et al
    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 7:1-8. doi: 10.1080/10428194.2018.1433297.
    PubMed     Text format     Abstract available


  32. FLOWERS CR, Nabhan C, Kay NE, Mato A, et al
    Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study.
    Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860.
    PubMed     Text format     Abstract available


  33. TORREBADELL M, Diaz-Beya M, Kalko SG, Pratcorona M, et al
    A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 2:1-11. doi: 10.1080/10428194.2017.1422859.
    PubMed     Text format     Abstract available


    January 2018
  34. SCIUME M, Fracchiolla NS, Cortelezzi A
    Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jan 31:1-2. doi: 10.1080/10428194.2018.1429603.
    PubMed     Text format    


  35. ZHANG Y, Qu S, Wang Q, Li J, et al
    A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Leuk Lymphoma. 2018 Jan 31:1-3. doi: 10.1080/10428194.2018.1427855.
    PubMed     Text format    


  36. ANDO T, Kojima K, Sano H, Kidoguchi K, et al
    Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
    Leuk Lymphoma. 2018 Jan 31:1-4. doi: 10.1080/10428194.2018.1427859.
    PubMed     Text format    


  37. RICARD L, Abisror N, Droin N, Selimoglu-Buet D, et al
    Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2018 Jan 25:1-3. doi: 10.1080/10428194.2018.1427857.
    PubMed     Text format    


  38. PANDEY G, Bakhshi S, Thakur B, Jain P, et al
    Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 18:1-13. doi: 10.1080/10428194.2017.1422865.
    PubMed     Text format     Abstract available


  39. GUILLEM V, Calabuig M, Brunet S, Esteve J, et al
    Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
    Leuk Lymphoma. 2018 Jan 18:1-11. doi: 10.1080/10428194.2017.1422858.
    PubMed     Text format     Abstract available


  40. LENNMYR EB, Kozlowski P, Ahlberg L, Bernell P, et al
    Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.
    Leuk Lymphoma. 2018 Jan 18:1-4. doi: 10.1080/10428194.2017.1416369.
    PubMed     Text format    


  41. BODDU P, Kantarjian H, Ravandi F, Garcia-Manero G, et al
    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864.
    PubMed     Text format    


  42. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  43. YANG M, Xing S, Ou HL, Zhang L, et al
    Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS.
    Leuk Lymphoma. 2018 Jan 16:1-9. doi: 10.1080/10428194.2017.1421754.
    PubMed     Text format     Abstract available


  44. ZHOU H, Xu RZ, Gu Y, Shi PF, et al
    Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 15:1-13. doi: 10.1080/10428194.2017.1390229.
    PubMed     Text format     Abstract available


  45. SHAO H, Zeng Z, Cen J, Zhang J, et al
    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Leuk Lymphoma. 2018 Jan 15:1-7. doi: 10.1080/10428194.2017.1422860.
    PubMed     Text format     Abstract available


  46. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed     Text format    


  47. HANNON M, Wilde L, Nwaoduah N, Kasner M, et al
    Chronic myelomonocytic leukemia with central nervous system involvement.
    Leuk Lymphoma. 2018 Jan 11:1-2. doi: 10.1080/10428194.2017.1422866.
    PubMed     Text format    


  48. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


    December 2017
  49. HANIF A, Wang ES, Thompson JE, Baron JI, et al
    Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595.
    PubMed     Text format    


  50. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  51. GAY ND, Kozin E, Okada C, Danilov AV, et al
    Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1410890.
    PubMed     Text format    


  52. HALDER A, Nayak KB, Chakraborty S
    Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1406089.
    PubMed     Text format    


  53. LI H, Zhang W, Kuang P, Ye Y, et al
    Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Dec 7:1-9. doi: 10.1080/10428194.2017.1406933.
    PubMed     Text format     Abstract available


  54. HERNANDEZ-GONZALEZ O, Ortiz-Zamudio JJ, Rodriguez-Pinal CJ, Alvarado-Morales I, et al
    Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1406090.
    PubMed     Text format     Abstract available


  55. LEI H, Wang W, Wu Y
    Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1403600.
    PubMed     Text format     Abstract available


  56. GUPTA SK, Bakhshi S, Chopra A, Kamal VK, et al
    Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1408087.
    PubMed     Text format     Abstract available


  57. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    



  58. XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York.
    Leuk Lymphoma. 2017;58.
    PubMed     Text format    


    November 2017
  59. RUGGIU M, Oberkampf F, Ghez D, Cony-Makhoul P, et al
    Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Nov 28:1-7. doi: 10.1080/10428194.2017.1397666.
    PubMed     Text format     Abstract available


  60. RIBERA JM, Morgades M, Montesinos P, Martino R, et al
    Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661.
    PubMed     Text format     Abstract available


  61. KANNA R, Choudhary G, Ramachandra N, Steidl U, et al
    STAT3 inhibition as a therapeutic strategy for leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668.
    PubMed     Text format     Abstract available


  62. PEI R, Si T, Lu Y, Zhou JX, et al
    Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-9. doi: 10.1080/10428194.2017.1399314.
    PubMed     Text format     Abstract available


  63. GOHIL SH, Maciocia N, Patrick P, Roberts T, et al
    LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399311.
    PubMed     Text format    


  64. PATNAIK MM
    The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-14. doi: 10.1080/10428194.2017.1399312.
    PubMed     Text format     Abstract available


  65. AYED AO, Parikh SA
    Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leuk Lymphoma. 2017 Nov 8:1-10. doi: 10.1080/10428194.2017.1397665.
    PubMed     Text format     Abstract available


  66. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  67. MCCURDY SR, Levis MJ
    Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 2:1-19. doi: 10.1080/10428194.2017.1393669.
    PubMed     Text format     Abstract available


    October 2017
  68. SATO R, Jacob J, Gaballa S
    Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1387907.
    PubMed     Text format    


  69. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Text format     Abstract available


  70. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Text format     Abstract available


  71. SALZER W, Bostrom B, Messinger Y, Perissinotti AJ, et al
    Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305.
    PubMed     Text format     Abstract available


  72. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  73. GEYER MB, Manjunath SH, Evans AG, Park JH, et al
    Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Leuk Lymphoma. 2017 Oct 18:1-5. doi: 10.1080/10428194.2017.1390237.
    PubMed     Text format    


  74. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  75. MITSUI-SEKINAKA K, Sekinaka Y, Ogura Y, Honda M, et al
    A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
    Leuk Lymphoma. 2017 Oct 18:1-3. doi: 10.1080/10428194.2017.1387901.
    PubMed     Text format    


  76. CORROCHER FA, Bueno de Paiva L, Duarte ASS, Ferro KP, et al
    Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Oct 17:1-4. doi: 10.1080/10428194.2017.1387900.
    PubMed     Text format    


  77. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


  78. LEE LJ, Toze CL, Huang SJT, Gillan TL, et al
    Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Leuk Lymphoma. 2017 Oct 16:1-8. doi: 10.1080/10428194.2017.1387904.
    PubMed     Text format     Abstract available


  79. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available


  80. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed     Text format    


  81. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    September 2017
  82. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed     Text format    


  83. APPLEBY N, O'Brien D, Quinn FM, Smyth L, et al
    Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-
    Leuk Lymphoma. 2017 Sep 19:1-10. doi: 10.1080/10428194.2017.1376746.
    PubMed     Text format     Abstract available


  84. ANDRITSOS LA, Grieselhuber NR, Anghelina M, Rogers KA, et al
    Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-4. doi: 10.1080/10428194.2017.1365853.
    PubMed     Text format    


  85. KREINITZ N, Polliack A, Tadmor T
    Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?
    Leuk Lymphoma. 2017 Sep 18:1-2. doi: 10.1080/10428194.2017.1376748.
    PubMed     Text format    


  86. RIZZOTTO L, Lai TH, Bottoni A, Woyach JA, et al
    Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-5. doi: 10.1080/10428194.2017.1376742.
    PubMed     Text format    


  87. VLIJM-KIEVIT A, Jorna NGE, Moll E, Pajkrt E, et al
    Acute lymphoblastic leukemia during the third trimester of pregnancy.
    Leuk Lymphoma. 2017 Sep 15:1-3. doi: 10.1080/10428194.2017.1375104.
    PubMed     Text format    


  88. MULANOVICH V, Kontoyiannis DP
    Acute myeloid leukemia and the infectious diseases consultant.
    Leuk Lymphoma. 2017 Sep 15:1-8. doi: 10.1080/10428194.2017.1365861.
    PubMed     Text format     Abstract available


  89. MESCHER C, Gilbertson D, Randall NM, Tarchand G, et al
    The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
    Leuk Lymphoma. 2017 Sep 14:1-8. doi: 10.1080/10428194.2017.1375109.
    PubMed     Text format     Abstract available


  90. VAUGHN JL, Kline D, Denlinger NM, Andritsos LA, et al
    Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
    Leuk Lymphoma. 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744.
    PubMed     Text format    


  91. TAVARES M, Lemiale V, Mokart D, Pene F, et al
    Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375106.
    PubMed     Text format     Abstract available


  92. PULA A, Stawiski K, Braun M, Iskierka-Jazdzewska E, et al
    Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Leuk Lymphoma. 2017 Sep 11:1-11. doi: 10.1080/10428194.2017.1375101.
    PubMed     Text format     Abstract available


  93. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Text format     Abstract available


  94. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Text format     Abstract available


  95. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed     Text format    


  96. GURBUXANI S
    The web of microRNA in B lymphoblastic leukemia.
    Leuk Lymphoma. 2017;58:2024-2025.
    PubMed     Text format    


    August 2017
  97. HUANG A, Huang C, Tang G, Cheng H, et al
    Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Aug 31:1-11. doi: 10.1080/10428194.2017.1369072.
    PubMed     Text format     Abstract available


  98. BURGSTALLER S, Stauder R, Kuehr T, Lang A, et al
    A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Leuk Lymphoma. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070.
    PubMed     Text format     Abstract available


  99. CAO H, Xie J, Guo L, Han K, et al
    All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Aug 29:1-9. doi: 10.1080/10428194.2017.1365850.
    PubMed     Text format     Abstract available


  100. BODDU P, Kantarjian H, Garcia-Manero G, Ravandi F, et al
    Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 25:1-4. doi: 10.1080/10428194.2017.1365857.
    PubMed     Text format    


  101. FALANTES J, Pleyer L, Thepot S, Almeida AM, et al
    Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Leuk Lymphoma. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854.
    PubMed     Text format     Abstract available


  102. IACCARINO L, Ottone T, Hasan SK, Divona M, et al
    Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2017 Aug 24:1-3. doi: 10.1080/10428194.2017.1369067.
    PubMed     Text format    


  103. SI T, Lu Y, Li F, Jiang L, et al
    High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 24:1-7. doi: 10.1080/10428194.2017.1324157.
    PubMed     Text format     Abstract available



  104. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  105. CRUZ NM, Sugita M, Ewing-Crystal N, Lam L, et al
    Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 10:1-5. doi: 10.1080/10428194.2017.1361023.
    PubMed     Text format    


  106. JALBUT MM, Brunner AM, Amrein PC, Ballen KK, et al
    Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361028.
    PubMed     Text format    


  107. CHEN X, Dou H, Wang X, Huang Y, et al
    KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1361025.
    PubMed     Text format     Abstract available


  108. CAYSSIALS E, Tartarin F, Guilhot J, Sorel N, et al
    Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1357178.
    PubMed     Text format    


  109. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


  110. KIVIOJA JL, Lopez Marti JM, Kumar A, Kontro M, et al
    Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
    PubMed     Text format     Abstract available


  111. DIRSE V, Norvilas R, Gineikiene E, Matuzeviciene R, et al
    ETV6 and NOTCH1 germline variants in adult acute leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-3. doi: 10.1080/10428194.2017.1359742.
    PubMed     Text format    


  112. SESE L, Rivaud E, Bron C, Leblond V, et al
    Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-4. doi: 10.1080/10428194.2017.1357170.
    PubMed     Text format    


  113. MULCAHY A, Mulligan SP, Shumack SP
    Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1349903.
    PubMed     Text format    


  114. WANG A, Cai X, Qiang P, Duan Q, et al
    Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
    Leuk Lymphoma. 2017 Aug 1:1-3. doi: 10.1080/10428194.2017.1357176.
    PubMed     Text format    


    July 2017
  115. YANADA M, Mori J, Aoki J, Harada K, et al
    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma. 2017 Jul 28:1-9. doi: 10.1080/10428194.2017.1357173.
    PubMed     Text format     Abstract available


  116. GEYER MB, Tallman MS
    Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.
    Leuk Lymphoma. 2017 Jul 28:1-3. doi: 10.1080/10428194.2017.1355971.
    PubMed     Text format    


  117. KONG J, Zhao XS, Qin YZ, Zhu HH, et al
    The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 26:1-6. doi: 10.1080/10428194.2017.1352091.
    PubMed     Text format     Abstract available


  118. ALDOSS I, Stein AS
    Advances in adult acute lymphoblastic leukemia therapy.
    Leuk Lymphoma. 2017 Jul 26:1-18. doi: 10.1080/10428194.2017.1354372.
    PubMed     Text format     Abstract available


  119. STRICKLER N, Balabanov S, Casauro K, Schanz U, et al
    Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
    Leuk Lymphoma. 2017 Jul 21:1-8. doi: 10.1080/10428194.2017.1352090.
    PubMed     Text format     Abstract available


  120. GONZALEZ-GASCON Y MARIN I, Hernandez-Sanchez M, Rodriguez-Vicente AE, Puiggros A, et al
    Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jul 21:1-10. doi: 10.1080/10428194.2017.1349901.
    PubMed     Text format     Abstract available


  121. ENGLAND JT, Leitch HA
    Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349904.
    PubMed     Text format    


  122. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  123. ALLAN JN, Roboz GJ, Askin G, Ritchie E, et al
    CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1352089.
    PubMed     Text format     Abstract available


  124. SHORT NJ, Kantarjian H, Ravandi F, Huang X, et al
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
    PubMed     Text format     Abstract available


  125. RAUSCH CR, Marini BL, Benitez LL, Elias A, et al
    PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia dagger.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349902.
    PubMed     Text format     Abstract available


  126. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  127. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Text format     Abstract available


  128. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Text format     Abstract available


  129. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Text format     Abstract available


  130. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed     Text format    


  131. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed     Text format    


  132. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed     Text format    


  133. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Text format     Abstract available


  134. CALVELLO C, Rocca B, Klersy C, Zappatore R, et al
    Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1346252.
    PubMed     Text format     Abstract available


  135. SALMOIRAGHI S, Rambaldi A, Spinelli O
    TP53 in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-12. doi: 10.1080/10428194.2017.1344839.
    PubMed     Text format     Abstract available


  136. XU W, Li X, Quan L, Yao J, et al
    Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-10. doi: 10.1080/10428194.2017.1346253.
    PubMed     Text format     Abstract available


  137. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


  138. XU L, Zhang M, Li H, Guan W, et al
    SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-13. doi: 10.1080/10428194.2017.1344843.
    PubMed     Text format     Abstract available


    June 2017
  139. KATKISH LA, Rangaraju S, Rector TS, Gravely AA, et al
    Incidence of unprovoked venous thromboembolic events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 27:1-3. doi: 10.1080/10428194.2017.1341979.
    PubMed     Text format    


  140. SANDOVAL-SUS JD, Chavez JC, Dalia S, Naqvi SMH, et al
    Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1323271.
    PubMed     Text format     Abstract available


  141. BORUTINSKAITE V, Virksaite A, Gudelyte G, Navakauskiene R, et al
    Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1339881.
    PubMed     Text format     Abstract available


  142. MAFFEI R, Fiorcari S, Martinelli S, Benatti S, et al
    Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Leuk Lymphoma. 2017 Jun 22:1-11. doi: 10.1080/10428194.2017.1339872.
    PubMed     Text format     Abstract available


  143. SANIKOMMU SR, Clemente MJ, Chomczynski P, Afable MG 2nd, et al
    Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).
    Leuk Lymphoma. 2017 Jun 20:1-7. doi: 10.1080/10428194.2017.1339880.
    PubMed     Text format     Abstract available


  144. VILLEMAGNE SANCHEZ LA, O'Callaghan C, Gough K, Hall K, et al
    Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 15:1-10. doi: 10.1080/10428194.2017.1337114.
    PubMed     Text format     Abstract available


  145. KANSAGRA A, Dahiya S, Litzow M
    Continuing challenges and current issues in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jun 11:1-16. doi: 10.1080/10428194.2017.1335397.
    PubMed     Text format     Abstract available


  146. FARSHCHI ZARABI S, Chan S, Gupta V, Khalaf D, et al
    Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
    Leuk Lymphoma. 2017 Jun 9:1-4. doi: 10.1080/10428194.2017.1323273.
    PubMed     Text format    


  147. DROIN N, Lucas N, Parinet V, Selimoglu-Buet D, et al
    Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.
    Leuk Lymphoma. 2017 Jun 8:1-5. doi: 10.1080/10428194.2017.1330468.
    PubMed     Text format     Abstract available


  148. LARSEN CM, Villarraga HR, Begna KH, Litzow MR, et al
    Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1323268.
    PubMed     Text format    


  149. TIONG IS, Tan P, McManus J, Cummings N, et al
    Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1334122.
    PubMed     Text format    


  150. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  151. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323267.
    PubMed     Text format     Abstract available


  152. BHATT VR, Gundabolu K, Koll T, Maness LJ, et al
    Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1323275.
    PubMed     Text format     Abstract available


  153. SOLE C, Martinez D, Gine E, Gonzalez-Farre B, et al
    Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-4. doi: 10.1080/10428194.2017.1330470.
    PubMed     Text format    


  154. NGUYEN D, Haley L, Pallavajjala A, Gojo I, et al
    Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1324163.
    PubMed     Text format    


  155. WEBSTER JA, Pratz KW
    Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Leuk Lymphoma. 2017 Jun 2:1-14. doi: 10.1080/10428194.2017.1330956.
    PubMed     Text format     Abstract available


  156. CHAOUI D, Choquet S, Sanhes L, Mahe B, et al
    Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
    Leuk Lymphoma. 2017;58:1366-1375.
    PubMed     Text format     Abstract available


  157. HANDUNNETTI SM, Polliack A, Tam CS
    Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?
    Leuk Lymphoma. 2017;58:1281-1282.
    PubMed     Text format    


  158. WENDTNER CM, Gregor M
    Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 1:1-11. doi: 10.1080/10428194.2017.1330474.
    PubMed     Text format     Abstract available


  159. PIGGIN A, Bayly E, Tam CS
    Novel agents versus chemotherapy as frontline treatment of CLL.
    Leuk Lymphoma. 2017;58:1320-1324.
    PubMed     Text format     Abstract available


    May 2017
  160. GAFTER-GVILI A
    G6PD deficiency and fungal infections in patients with acute myeloid leukemia: less enzyme more fungus.
    Leuk Lymphoma. 2017 May 31:1-2. doi: 10.1080/10428194.2017.1330478.
    PubMed     Text format    


  161. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596.
    PubMed     Text format     Abstract available


  162. LEE SE, Choi SY, Kim SH, Song HY, et al
    Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
    Leuk Lymphoma. 2017 May 25:1-9. doi: 10.1080/10428194.2017.1320711.
    PubMed     Text format     Abstract available


  163. SAINI L, Brandwein J, Szkotak A, Ghosh S, et al
    Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-8. doi: 10.1080/10428194.2017.1326032.
    PubMed     Text format     Abstract available


  164. XU X, Nagel S, Quentmeier H, Wang Z, et al
    KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-10. doi: 10.1080/10428194.2017.1324156.
    PubMed     Text format     Abstract available


  165. HOSHINO T, Taki T, Takada S, Hatsumi N, et al
    Spontaneous remission of adult acute myeloid leukemia with t(8;16)(p11;p13)/MOZ-CBP fusion.
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1320712.
    PubMed     Text format    


  166. BRECCIA M, Efficace F
    Are chronic myeloid leukemia patients ready to stop long-term treatment?
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1330476.
    PubMed     Text format    


  167. LARSON RA
    Managing CNS disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 23:1-11. doi: 10.1080/10428194.2017.1326597.
    PubMed     Text format     Abstract available


  168. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Text format     Abstract available


  169. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed     Text format    


  170. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed     Text format    


  171. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Text format     Abstract available


  172. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Text format     Abstract available


  173. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


  174. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Text format     Abstract available


  175. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Text format     Abstract available


  176. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Text format     Abstract available


  177. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Text format     Abstract available


  178. BUTLER JS, Qiu YH, Zhang N, Yoo SY, et al
    Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
    Leuk Lymphoma. 2017;58:1207-1218.
    PubMed     Text format     Abstract available


    April 2017
  179. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed     Text format    


  180. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  181. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Text format     Abstract available


  182. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Text format     Abstract available


  183. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  184. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Text format     Abstract available


  185. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed     Text format    


  186. BEAUPIN LK, Bostrom B, Barth MJ, Franklin I, et al
    Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Leuk Lymphoma. 2017;58:766-772.
    PubMed     Text format     Abstract available


    March 2017
  187. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Text format     Abstract available


  188. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed     Text format    


  189. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Text format     Abstract available


  190. KO DR, Jang JE, Chung SP, Lee JW, et al
    Usefulness of the delta neutrophil index as an ancillary test in the emergency department for the early diagnosis of suspected acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Mar 2:1-8. doi: 10.1080/10428194.2017.1296142.
    PubMed     Text format     Abstract available


  191. DARAKI A, Zachaki S, Rosmaraki F, Kalomoiraki M, et al
    Association of GSTP1 inactivating polymorphism with acute myeloid leukemia and its specific chromosomal abnormalities.
    Leuk Lymphoma. 2017 Mar 2:1-3. doi: 10.1080/10428194.2017.1295148.
    PubMed     Text format    


    February 2017
  192. OKA S, Ono K, Nohgawa M
    Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Leuk Lymphoma. 2017 Feb 28:1-3. doi: 10.1080/10428194.2017.1295146.
    PubMed     Text format    


  193. ESKAZAN AE
    Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-2. doi: 10.1080/10428194.2017.1295145.
    PubMed     Text format    


  194. VILIA MG, Fonte E, Veliz Rodriguez T, Tocchetti M, et al
    The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-7. doi: 10.1080/10428194.2017.1295142.
    PubMed     Text format     Abstract available


  195. ISKIERKA-JAZDZEWSKA E, Hus M, Giannopoulos K, Madro E, et al
    Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1292353.
    PubMed     Text format    


  196. ORGEL E, Mueske NM, Sposto R, Gilsanz V, et al
    A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-9. doi: 10.1080/10428194.2017.1289526.
    PubMed     Text format     Abstract available


  197. KHAN N, Hantel A, Knoebel RW, Artz A, et al
    Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-7. doi: 10.1080/10428194.2017.1289524.
    PubMed     Text format     Abstract available


  198. THOMAS JS, Jagasia M, Vnencak-Jones CL
    Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Feb 14:1-4. doi: 10.1080/10428194.2017.1287362.
    PubMed     Text format    


  199. XIA D, Zhang YT, Xu GP, Yan WW, et al
    Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells.
    Leuk Lymphoma. 2017 Feb 13:1-10. doi: 10.1080/10428194.2017.1287358.
    PubMed     Text format     Abstract available


  200. MU Q, Guo L, Hu Y, Sheng L, et al
    SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
    Leuk Lymphoma. 2017 Feb 9:1-3. doi: 10.1080/10428194.2017.1287357.
    PubMed     Text format    


  201. MAITI A, Cortes J, Ferrajoli A, Estrov Z, et al
    Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 9:1-6. doi: 10.1080/10428194.2017.1283030.
    PubMed     Text format    


  202. VOJDEMAN FJ, Herman SE, Kirkby N, Wiestner A, et al
    Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 7:1-7. doi: 10.1080/10428194.2017.1285027.
    PubMed     Text format     Abstract available


  203. REBECHI MT, Pratz KW
    Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.
    Leuk Lymphoma. 2017 Feb 6:1-11. doi: 10.1080/10428194.2017.1283031.
    PubMed     Text format     Abstract available


    January 2017
  204. NAGEL S, Pommerenke C, Meyer C, Kaufmann M, et al
    Identification of a tumor suppressor network in T-cell leukemia.
    Leuk Lymphoma. 2017 Jan 31:1-15. doi: 10.1080/10428194.2017.1283029.
    PubMed     Text format     Abstract available


  205. KRULL K, Kunstreich M, Klasen-Sansone J, Kloetgen A, et al
    Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial.
    Leuk Lymphoma. 2017 Jan 31:1-10. doi: 10.1080/10428194.2017.1280605.
    PubMed     Text format     Abstract available


  206. LOEFF FC, van Egmond HM, Nijmeijer BA, Falkenburg JH, et al
    Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Leuk Lymphoma. 2017 Jan 31:1-14. doi: 10.1080/10428194.2017.1281411.
    PubMed     Text format     Abstract available


  207. NAN X, Qin Q, Gentille C, Ensor J, et al
    Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center.
    Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2016.1277386.
    PubMed     Text format     Abstract available


  208. CHANG YC, Lo WJ, Huang YT, Lin CL, et al
    Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1280604.
    PubMed     Text format     Abstract available


  209. ZHOU G, Cao Y, Dong W, Lin Y, et al
    The clinical characteristics and prognostic significance of AID, miR-181b, and miR-155 expression in adult patients with de novo B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1283028.
    PubMed     Text format     Abstract available


  210. CRAMPE M, Shakkak F, Kelly J, Hodgson A, et al
    Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Leuk Lymphoma. 2017 Jan 25:1-6. doi: 10.1080/10428194.2017.1281413.
    PubMed     Text format    


  211. HOLKOVA B, Yazbeck V, Kmieciak M, Bose P, et al
    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2017 Jan 19:1-9. doi: 10.1080/10428194.2016.1276287.
    PubMed     Text format     Abstract available


  212. ALMAMUN M, Kholod O, Stuckel AJ, Levinson BT, et al
    Inferring a role for methylation of intergenic DNA in the regulation of genes aberrantly expressed in precursor B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jan 17:1-12. doi: 10.1080/10428194.2016.1272683.
    PubMed     Text format     Abstract available


  213. RAMACHANDRAN SS, Muiwo P, Ahmad HM, Pandey RM, et al
    miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 16:1. doi: 10.1080/10428194.2016.1272681.
    PubMed     Text format    


  214. EL-FATTAH MA
    Second malignancies in survivors of chronic myelomonocytic leukemia: a U.S. population-based study.
    Leuk Lymphoma. 2017 Jan 16:1-7. doi: 10.1080/10428194.2016.1276289.
    PubMed     Text format    


  215. YAN JS, Li YD, Liu SH, Yin QQ, et al
    The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Leuk Lymphoma. 2017 Jan 16:1-7. doi: 10.1080/10428194.2016.1272690.
    PubMed     Text format    


  216. ESKAZAN AE
    Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?
    Leuk Lymphoma. 2017 Jan 16:1-5. doi: 10.1080/10428194.2016.1272685.
    PubMed     Text format    


  217. GUO Y, Strickland SA, Mohan S, Li S, et al
    MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-15. doi: 10.1080/10428194.2016.1272680.
    PubMed     Text format     Abstract available


  218. PETERSON LF, Lo MC, Liu Y, Gianolla D, et al
    Induction of p53 suppresses chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-14. doi: 10.1080/10428194.2016.1272682.
    PubMed     Text format     Abstract available


    December 2016
  219. SUMI M, Sato K, Kaiume H, Takeda W, et al
    Second cord blood transplantation and interferon-alpha maintenance therapy for relapsed Ph+ acute lymphoblastic leukemia with the T315I mutation.
    Leuk Lymphoma. 2016 Dec 21:1-3. doi: 10.1080/10428194.2016.1266623.
    PubMed     Text format    


  220. XIA X, Duan Y, Cui J, Jiang J, et al
    Association of methylenetetrahydrofolate reductase gene-gene interaction and haplotype with susceptibility to acute lymphoblastic leukemia in Chinese children.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  221. ZHANG L, McGraw KL, Sallman DA, List AF, et al
    The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  222. KUILA N, Nayak KB, Halder A, Agatheeswaran S, et al
    Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  223. GIRIDHAR KV, Shanafelt T, Tosh PK, Parikh SA, et al
    Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  224. YAN H, Zhang DY, Li X, Yuan XQ, et al
    Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  225. KENG MB, Keng HC, Tan BH, Wong GC, et al
    High risk of invasive fungal infections in adult acute lymphoblastic leukemia patients receiving induction and salvage chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  226. YEKTAEI-KARIN E, Zovko A, Nilsson A, Nasman-Glaser B, et al
    Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  227. SAVASOGLU K, Payzin KB, Ozdemirkiran F, Subasioglu A, et al
    The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  228. VINHAS R, Cordeiro M, Pedrosa P, Fernandes AR, et al
    Current trends in molecular diagnostics of chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  229. SHANMUGAM V, Dorfman DM
    An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  230. VAN DE REE-PELLIKAAN C, van der Straten L, Riedl JA, Levin MD, et al
    High coincidence of chronic lymphocytic leukemia and myeloproliferative neoplasms: detection bias or a clue to a common pathophysiological path?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  231. VEY N, Prebet T, Thalamas C, Charbonnier A, et al
    Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  232. PESSINA C, Basilico C, Genoni A, Meroni E, et al
    A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    November 2016
  233. KOMMERS IO, Bartley PA, Budgen B, Latham S, et al
    Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  234. ASKLID A, Winqvist M, Eketorp Sylvan S, Mattsson A, et al
    Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  235. ORLANDI EM, Elena C, Bono E
    Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  236. SHANAFELT TD, Parikh SA, Noseworthy PA, Goede V, et al
    Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  237. GURU MURTHY GS, Dhakal I, Mehta P
    Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  238. MAURO FR, Carella AM, Molica S, Paoloni F, et al
    Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  239. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI).
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  240. PAN J, Zhang Y, Zhao YL, Yang JF, et al
    Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  241. COMA M, Tothova E, Guman T, Hajikova M, et al
    Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  242. BALASUBRAMANIAN P, Chopra A, Verma D, Singh IK, et al
    Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  243. YAP KL, Furtado LV, Kiyotani K, Curran E, et al
    Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  244. HUSSAINI MO, Rehman A, Chavez JC, Pinilla-Ibarz J, et al
    EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  245. MIR R, Najar IA, Guru S, Javaid J, et al
    A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  246. NAUMANN JA, Gordon PM
    In vitro model of leukemia cell migration across the blood-cerebrospinal fluid barrier.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  247. FINNES HD, Chaffee KG, Call TG, Ding W, et al
    Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  248. VAN DEN NESTE E
    Chronic lymphocytic leukemia management in the elderly: let us not forget the patient - even on a busy day.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  249. MINA R, D'Agostino M, Cerrato C, Gay F, et al
    Plasma cell leukemia: update on biology and therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  250. DURANI U, Go RS
    Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  251. ROSSI D, Gerber B, Stussi G
    Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    October 2016
  252. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  253. YANG W, Tran P, Khan Z, Rezk S, et al
    MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  254. BRAUN M, Pastorczak A, Fendler W, Madzio J, et al
    Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  255. CRASSINI K, Shen Y, Mulligan S, Giles Best O, et al
    Modeling the chronic lymphocytic leukemia microenvironment in vitro.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  256. GOLDSCHMIDT N, Rund D
    Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  257. SEFTEL MD, Kuruvilla J, Kouroukis T, Banerji V, et al
    The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  258. POOLE A, Girard N, Clayton F, Tantravahi SK, et al
    Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  259. BRENNER AK, Aasebo E, Hernandez-Valladares M, Selheim F, et al
    Rethinking the role of osteopontin in human acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  260. DE LUCA L, D'Arena G, Simeon V, Trino S, et al
    Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  261. ZAHID MF, Lasho TL, Finke C, Ketterling RP, et al
    Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  262. SEYMOUR JF, Dohner H, Minden MD, Stone R, et al
    Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  263. GAO N, Yu WZ, Guo NJ, Wang XX, et al
    Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  264. NAKASE K, Kita K, Kyo T, Katayama N, et al
    High expression of interleukin-2 receptor alpha-chain (CD25) in myelodysplastic syndrome preceding acute myeloid leukemia and chronic myeloid leukemia in myeloid blast crisis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  265. BENADIBA J, Rosilio C, Nebout M, Heimeroth V, et al
    Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  266. LITWINSKA Z, Machalinski B
    miRNAs in chronic myeloid leukemia: small molecules, essential function.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  267. FRIDLE C, Medinger M, Wilk MC, Seipel K, et al
    Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  268. WANG W, Foerner E, Buss E, Jauch A, et al
    Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  269. BOHN JP, Wanner D, Steurer M
    Ibrutinib for relapsed refractory hairy cell leukemia variant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  270. ZHAO XS, Qin YZ, Liu YR, Chang YJ, et al
    The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  271. QIN YZ, Jiang Q, Lai YY, Jiang H, et al
    Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  272. KOKA R, Mainor CB, Banerjee A, Baer MR, et al
    Concomitant amplification of the MLL gene on a ring chromosome and a homogeneously staining region (hsr) in acute myeloid leukemia: mechanistic implications.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  273. PELED JU, Jenq RR
    Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  274. ROBAK T, Warzocha K, Govind Babu K, Kulyaba Y, et al
    Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  275. MORITA K, Nakamura F, Sakuishi K, Yamamoto T, et al
    Successful management of chronic myeloid leukemia with a complication of anti-SRP antibody-associated myopathy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  276. ZHANG W, Yang Y, Xie L, Ye Y, et al
    The first case of acute T-cell lymphoblastic leukemia containing the e19a2 BCR-ABL1 transcript: a durable molecular response using imatinib-based chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  277. YANADA M, Yano S, Kanamori H, Gotoh M, et al
    Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  278. YOSHIDA S, Tuscano E, Duong C, Chung J, et al
    Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  279. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  280. MEDINA D, David K, Lin Y, Schaar D, et al
    Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  281. MAITI A, Cortes JE, Brown YD, Kantarjian HM, et al
    Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  282. LI H, Zhang W, Yi D, Ye Y, et al
    Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  283. TESTI AM, Moleti ML, Canichella M, Mohamed S, et al
    Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  284. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  285. VALLIPURAM J, Dhalla S, Bell CM, Dresser L, et al
    Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    August 2016
  286. FARHADFAR N, Cerquozzi S, Hessenauer MR, Litzow MR, et al
    Acute leukemia in pregnancy: a single institution experience with 23 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  287. KLIMAN D, Barnett M, Broady R, Forrest D, et al
    Comparison of a pediatric-inspired treatment protocol versusstandard-intensity chemotherapy for young adults with standard-riskBCR-ABL negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  288. WIERZBOWSKA A, Wawrzyniak E, Siemieniuk-Rys M, Kotkowska A, et al
    Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  289. MARTIN-TREJO JA, Nunez-Enriquez JC, Fajardo-Gutierrez A, Medina-Sanson A, et al
    Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  290. TCHENG M, Samudio I, Lee EA, Minden MD, et al
    The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  291. SORA F, Ponziani FR, Laurenti L, Chiusolo P, et al
    Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  292. BURKE MJ, Rheingold SR
    Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  293. XU Y, Wertheim G, Morrissette JJ, Bagg A, et al
    BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  294. MEYER-PANNWITT V, Steinbrecher D, Stilgenbauer S, Mertens D, et al
    Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  295. VERGER E, Rattarittamrong E, Letort G, Raffoux E, et al
    Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  296. MCGOVERN B, Quinn F, Andrews C, Jeffers M, et al
    NOTCH1 mutation in type II Hodgkin transformation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  297. LEE CJ, Shiraz P, Muffly L
    Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  298. CALDEMEYER L, Akard LP
    Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  299. GEMENETZI K, Galigalidou C, Vlachonikola E, Stalika E, et al
    Tp53 gene p72R polymorphism in chronic lymphocytic leukemia: incidence and clinical significance amongst cases with unmutated immunoglobulin receptors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  300. MOSAAD YM, Elashery R, Darwish A, Sharaf Eldein OA, et al
    GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  301. LOZANO-SANTOS C, Garcia-Vela JA, Perez-Sanz N, Nova-Gurumeta S, et al
    Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naive chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  302. JEZISKOVA I, Semerad L, Dvorakova D, Janeckova V, et al
    Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  303. VOJDEMAN FJ, Van't Veer MB, Tjonnfjord GE, Ittala-Remes M, et al
    The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    July 2016
  304. DE BRAEKELEER M, Douet-Guilbert N, De Braekeleer E
    Prognostic impact of p15 gene aberrations in acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  305. BACHANOVA V
    Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  306. MARIETTE C, Tavernier E, Hocquet D, Huynh A, et al
    Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  307. VATEL O, Aumont C, Mathy V, Petit M, et al
    Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  308. LAW AD, Dong Hwan Kim D, Lipton JH
    Pregnancy: part of life in chronic myelogenous leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  309. YIN Y, Li J, Yan W, Cheng Z, et al
    CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  310. PETTIT K, Stock W, Walter RB
    Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
    Leuk Lymphoma. 2016;57:1527-33.
    PubMed     Text format     Abstract available


    June 2016
  311. KUTSCH N, Busch R, Bahlo J, Mayer J, et al
    FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  312. ZHANG ZX, Shen CF, Shou LH, Fang Q, et al
    IRF-3 gene polymorphisms are associated with the susceptibility to and the survival in chronic lymphocytic leukemia and could also serve as an auxiliary index.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  313. BOMMANNAN K, Totadri S, Sachdeva MU, Naseem S, et al
    p210 BCR-ABL1 positive pediatric B-lineage acute lymphoblastic leukemia presenting with hypercalcemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  314. GUPTA SK, Bakhshi S, Kumar L, Kamal VK, et al
    Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  315. RASKOVA KAFKOVA L, Navrkalova V, Jarosova M, Loja T, et al
    Ability to downregulate the level of cyclin-dependent kinase inhibitor p27 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  316. KENEALY M, Patton N, Filshie R, Nicol A, et al
    Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  317. BEAUVERD Y, Cortes B, Masouye I, Chalandon Y, et al
    Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  318. YAMAZAKI E, Kanamori H, Itabashi M, Ogusa E, et al
    Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  319. DRENBERG CD, Buelow DR, Pounds SB, Wang YD, et al
    Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    May 2016
  320. MICHALLET M, Sobh M, Labussiere H, Lombard C, et al
    Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  321. MASON EF, Brown RD, Szeto DP, Gibson CJ, et al
    Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  322. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  323. GAO YJ, Guo Y, Hu SY, Zhu YP, et al
    Philadelphia chromosome-positive acute lymphoblastic leukemia in China: a retrospective study from the Chinese Childhood Cancer Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  324. KAY NE, Sassoon T, Secreto C, Sinha S, et al
    Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  325. CHIEW MY, Boo NY, Voon K, Cheong SK, et al
    Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  326. PLESINGEROVA H, Librova Z, Plevova K, Libra A, et al
    COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  327. Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  328. KATSUSHIMA H, Fukuhara N, Ichikawa S, Ota Y, et al
    Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  329. GRAIN A, Sirvent A, Strullu M, Francoise M, et al
    Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bo
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  330. HEIBLIG M, Le Jeune C, Elhamri M, Balsat M, et al
    Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  331. FANG Q, Zhao X, Li Q, Li Y, et al
    IKZF1 alterations and expression of CRLF2 predict prognosis in adult Chinese patients with B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  332. Jun Ji, Dr Li Zhang, Yuan-Yuan Wu, Xiao-Yu Zhu, Su-Qing Lv, Xi-Zuo Sun, Induction of apoptosis by d-limonene is mediated by a caspase-dependent mitochondrial death pathway in human leukemia cells. December 2006;47(12):2617-2624. http://dx.doi.org/10.1
    Leuk Lymphoma. 2016;57:1242.
    PubMed     Text format    


  333. CRAMER P, Langerbeins P, Fischer K, Eichhorst B, et al
    Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?
    Leuk Lymphoma. 2016;57:987-90.
    PubMed     Text format    


  334. GOEBELER ME, Bargou R
    Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Leuk Lymphoma. 2016;57:1021-32.
    PubMed     Text format     Abstract available


  335. HORNER TJ, Williams VC, Giampietro P, Witman PA, et al
    Long-term follow-up of previously treated and treatment-naive patients who received tositumomab and I-131 tositumomab.
    Leuk Lymphoma. 2016;57:1238-40.
    PubMed     Text format    


    April 2016
  336. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  337. CHEN L, Wu Y, You Y, Xiao M, et al
    A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  338. MCDOWELL MM, Zhu X, Agarwal N, Nikiforova MN, et al
    Response of relapsed central nervous system hairy cell leukemia to vemurafenib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  339. LI J, Best OG, Mulligan SP, Fernando SL, et al
    Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  340. TANG Y, Wei X, Chen J, Du Y, et al
    Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  341. MCGREGOR AK, Moulton D, Bown N, Cuthbert G, et al
    The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia - Response to Rashidi et al.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  342. IVANOV OFVERHOLM I, Tran AN, Olsson L, Zachariadis V, et al
    Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  343. FARRELL K, Fyfe A, Allan J, Tait RC, et al
    An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  344. TURHAN AG
    Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  345. FENG J, Zhang W, Wu J, Gao S, et al
    Effect of initial absolute monocyte count on survival outcome of patients with de novo non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  346. DENU RA, Lobo RH, Mattison RJ
    Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  347. CRUZ NG, Ribeiro AF, Gloria AB, Abbas S, et al
    Characterization of NPM1, FLT3, and IDH1 mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  348. WANG SY, Chen WL, Wang ZC, Li XF, et al
    High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  349. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: molecularly contaminated, but not defined.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  350. SU L, Fei Y, Wei X, Guo J, et al
    Associations of parental occupational exposure to extremely low-frequency magnetic fields with childhood leukemia risk.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  351. CHEN LS, Yang JY, Liang H, Cortes JE, et al
    Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    March 2016
  352. RASHIDI A, Wolach O, El-Jawahri A, Ho VT, et al
    The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  353. CASSADAY RD, Alan Potts D Jr, Stevenson PA, Bar M, et al
    Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  354. DIRSE V, Gineikiene E, Zvirblis T, Bertasiute R, et al
    Single nucleotide polymorphism array analysis of clonal evolution in younger adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  355. CAVAZZINI F, Lista E, Quaglia FM, Formigaro L, et al
    Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  356. PATKAR N, Ghodke K, Joshi S, Chaudhary S, et al
    Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  357. VIDAL L, Gurion R, Ram R, Raanani P, et al
    Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  358. BELTON A, Xian L, Huso T, Koo M, et al
    STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  359. Peihua Luo, Meili Lin, Meihua Lin, Yiyu Chen, Bo Yang, Qiaojun He, Function of retinoid acid receptor a and p21 in all-trans-retinoic acid-induced acute T-lymphoblastic leukemia apoptosis. July 2009;50(7):1183-1189. http://dx/doi.org/10.1080/104281909
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  360. NICOLATO A, Nouer SA, Garnica M, Portugal R, et al
    Invasive fungal diseases in patients with acute lymphoid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  361. Wei Zhang, Bao-an Chen, Jun-fei Jin, You-ji He, and Yi-qi Niu, Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. November 2013;54(11):2506-2516. http://dx.doi.org/10.31
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  362. DESHPANDE PA, Srivastava VM, Mani S, Anandhan S, et al
    Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  363. RANI L, Mathur N, Gogia A, Vishnubhatla S, et al
    Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    February 2016
  364. YAMAMOTO C, Ito S, Mashima K, Umino K, et al
    Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  365. SCHLIEMANN I, Oschlies I, Nagel I, Maria Murga Penas E, et al
    The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  366. AL-DARWISH M, Farhan N, Al-Jebreen A, Allam R, et al
    The contribution of multiple packed red blood cell transfusions toward cardiac and liver dysfunction in pediatric patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  367. ABEDIN S, Platanias LC
    Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  368. BORGE M, Delpino MV, Podaza E, Stanganelli C, et al
    Soluble RANKL production by leukemic cells in a case of chronic lymphocytic leukemia with bone destruction.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  369. DEBOER R, Koval G, Mulkey F, Wetzler M, et al
    Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  370. ASSAL A, Dong B, Khan H, Medavarapu R, et al
    Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  371. WANQUET A, Crocchiolo R, Furst S, Granata A, et al
    The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk mye
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  372. STYCZYNSKI J, Czyzewski K, Wysocki M, Zajac-Spychala O, et al
    Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  373. DRACHTMAN RA, Masterson M, Shenkerman A, Vijayanathan V, et al
    Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  374. KUANG P, Liu T, Pan L, Zhu H, et al
    Sustaining integrating imatinib and interferon-alpha into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  375. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  376. VIGNA E, Gentile M, Giagnuolo G, Recchia AG, et al
    Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  377. SAJAROFF EO, Mansini A, Rubio P, Alonso CN, et al
    B-cell acute lymphoblastic leukemia with mature phenotype and MLL rearrangement: report of five new cases and review of the literature.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  378. KO BW, Han J, Heo JY, Jang Y, et al
    Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  379. MAMEZ AC, Raffoux E, Chevret S, Lemiale V, et al
    Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  380. ANDERSEN MA, Vojdeman FJ, Andersen MK, Brown PN, et al
    Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    January 2016
  381. ORGEL E, Mueske NM, Sposto R, Gilsanz V, et al
    Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  382. KAPLAN JB, Altman JK, Platanias LC
    SNPing away to individualize induction therapy for acute myelogenous leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  383. WALKER AR, Wang H, Walsh K, Bhatnagar B, et al
    Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  384. OSTERBORG A, Udvardy M, Zaritskey A, Andersson PO, et al
    Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  385. MADDOCKS K, Hertlein E, Chen TL, Wagner AJ, et al
    A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  386. KAPELKO-SLOWIK K, Owczarek TB, Grzymajlo K, Urbaniak-Kujda D, et al
    Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  387. WENDTNER CM, Hallek M, Fraser GA, Michallet AS, et al
    Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  388. AYESH HAJ YOUSEF MH, Khassawneh B
    Granulocyte-colony stimulating factor induces disseminated intravascular coagulation in dormant acute promyelocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  389. HARA T, Matsumoto T, Shibata Y, Nakamura N, et al
    Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  390. SMIRNIKHINA SA, Lavrov AV, Chelysheva EY, Adilgereeva EP, et al
    Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  391. KATKISH L, Rector T, Ishani A, Gupta P, et al
    Incidence and severity of pseudohyperkalemia in chronic lymphocytic leukemia: a longitudinal analysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  392. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  393. GODWIN CD, Othus M, Powell MA, Buckley SA, et al
    Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  394. TANTRAVAHI SK, Szankasi P, Khorashad JS, Dao KH, et al
    A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza(R)) in Patients with Chronic Myelomonocytic Leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  395. LEE MH, Kim SY
    Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  396. RIZZIERI DA, Cooley S, Odenike O, Moonan L, et al
    An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  397. FELICE MS, Rossi JG, Alonso CN, Gallego MS, et al
    Experience with four consecutive BFM-based protocols for treatment of childhood with non-promyelocytic acute myeloblastic leukemia in Argentina.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  398. TAM CS, Polliack A
    Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  399. HEDLEY D, Shamas-Din A, Chow S, Sanfelice D, et al
    A Phase I Study of Elesclomol Sodium in Patients with Acute Myeloid Leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  400. ROTIN LE, Gronda M, Hurren R, Wang XM, et al
    Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  401. MILLER TP, Getz KD, Kavcic M, Li Y, et al
    A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  402. NIWA Y, Minami Y, Abe A, Hayakawa F, et al
    Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  403. AKARD LP, Bixby D
    Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  404. LU BY, Thanawala SU, Zochowski KC, Carroll WL, et al
    Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  405. ZENT CS
    Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  406. SANFORD D, Garcia-Manero G, Jorgensen J, Konoplev S, et al
    CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  407. THOTA S, Sekeres MA
    Combination therapies for MDS and AML: Does one plus one equal one?
    Leuk Lymphoma. 2016;57:505-6.
    PubMed     Text format    


  408. CARDONA ME, Simonson OE, Oprea II, Moreno PM, et al
    A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Leuk Lymphoma. 2016;57:183-92.
    PubMed     Text format     Abstract available


  409. RIVA E, Manrique Arechavaleta G, De Almeida C, Costa V, et al
    A novel e8a2 BCR-ABL1 fusion with insertion of MAST2 exon 2 in a four-way translocation t (1;17;9;22) (p35;q24;q44;q11) in a patient with chronic myeloid leukemia.
    Leuk Lymphoma. 2016;57:203-5.
    PubMed     Text format    


  410. LIPOWSKA-BHALLA G, Fagnano E, Illidge TM, Cheadle EJ, et al
    Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
    Leuk Lymphoma. 2016;57:1269-80.
    PubMed     Text format     Abstract available


  411. GORNIAK P, Budziszewska B, Pula B, Wasylecka M, et al
    Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.
    Leuk Lymphoma. 2016;57:1471-3.
    PubMed     Text format    


  412. MICHALLET AS, Sesques P, Rabe KG, Itti E, et al
    An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's Syndrome.
    Leuk Lymphoma. 2016;57:1474-7.
    PubMed     Text format    


  413. YE XN, Zhou XP, Wei JY, Xu GX, et al
    Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Leuk Lymphoma. 2016;57:1311-8.
    PubMed     Text format     Abstract available


    December 2015
  414. JAIN P, Verstovsek S, Wang W, Loghavi S, et al
    DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  415. GARG S, Shanmukhaiah C, Ghosh K, Madkaikar M, et al
    Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  416. CALLEA M, Bellacchio E, Fattori F, Bertini E, et al
    Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  417. ZENT CS, Bowen DA, Conte MJ, LaPlant BR, et al
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  418. SUN C, Wiestner A
    Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  419. ARAKI D, Othus M, Walter RB, Becker PS, et al
    Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  420. BROGILE L, Hijiya N, Helenowski IB, Dilley K, et al
    Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  421. TSURUSAWA M, Watanabe T, Gosho M, Mori T, et al
    Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  422. BABUSHOK DV, Bessler M, Olson TS
    Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  423. ZHENG C, Zhu X, Tang B, Zhang L, et al
    The impact of pre-transplantation minimal residual disease on outcome of intensified myeloablative cord blood transplantation for acute myeloid leukemia in first or second complete remission.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  424. SHI M, Neff JL, Jevremovic D, Morice WG, et al
    Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    



  425. Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2015 nov 16. [epub ahead of print]. http://dx.doi.org/10.3109/10428194.2015.1094692.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  426. NOH H, Park MS, Kim SH, Oh SJ, et al
    Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  427. MCGREGOR AK, Moulton D, Bown N, Cuthbert G, et al
    Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  428. ROZOVSKI U, Hazan-Halevy I, Barzilai M, Keating MJ, et al
    Metabolism pathways in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    November 2015
  429. PAREKH V, Peker D
    Clinicopathologic and cytogenetic characterization of therapy-related acute T lymphoblastic leukemia in adult population.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  430. MULLER D, Fischer K, Kaiser P, Eichhorst B, et al
    Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    October 2015
  431. WARTMAN LD, Fiala MA, Fletcher T, Hawkins ER, et al
    A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    May 2015
  432. PALACIOS F, Prieto D, Abreu C, Ruiz S, et al
    Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells.
    Leuk Lymphoma. 2015;56:1560-5.
    PubMed     Text format     Abstract available


  433. SHIN SY, Lee ST, Kim HJ, Jang JH, et al
    A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12.
    Leuk Lymphoma. 2015;56:1550-1.
    PubMed     Text format    


  434. TESTA U, Pelosi E
    MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias.
    Leuk Lymphoma. 2015;56:1466-74.
    PubMed     Text format     Abstract available


  435. TIAN H, Chen GH, Xu Y, Ma X, et al
    Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
    Leuk Lymphoma. 2015;56:1353-61.
    PubMed     Text format     Abstract available


  436. OHM L, Lundqvist A, Dickman P, Hoglund M, et al
    Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
    Leuk Lymphoma. 2015;56:1385-91.
    PubMed     Text format     Abstract available


  437. WASIK AM, Priebe V, Lord M, Jeppsson-Ahlberg A, et al
    Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Leuk Lymphoma. 2015;56:1425-31.
    PubMed     Text format     Abstract available


  438. ZHU L, Wang Z, Zheng X, Ding L, et al
    Haploidentical hematopoietic stem cell transplant with umbilical cord-derived multipotent mesenchymal cell infusion for the treatment of high-risk acute leukemia in children.
    Leuk Lymphoma. 2015;56:1346-52.
    PubMed     Text format     Abstract available


  439. ROY MOULIK N, Kumar A, Agrawal S, Awasthi S, et al
    Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2015;56:1379-84.
    PubMed     Text format     Abstract available


    March 2015
  440. FILANOVSKY K, Yacobi R, Vorst E, Barshack I, et al
    Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
    Leuk Lymphoma. 2015;56:823-5.
    PubMed     Text format    


  441. PATEL AB, Chen YH, Zhang Y, Frankfurt O, et al
    Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16).
    Leuk Lymphoma. 2015;56:817-9.
    PubMed     Text format    


  442. BARTRAM T, Burkhardt B, Wossmann W, Seidemann K, et al
    Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Munster Study Group.
    Leuk Lymphoma. 2015;56:814-6.
    PubMed     Text format    


  443. YAO C, Du W, Chen H, Xiao S, et al
    The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
    Leuk Lymphoma. 2015;56:755-62.
    PubMed     Text format     Abstract available


  444. COCCARO N, Tota G, Anelli L, Zagaria A, et al
    Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation.
    Leuk Lymphoma. 2015;56:826-8.
    PubMed     Text format    


  445. BIGLIARDI S, Morselli M, Potenza L, Coluccio V, et al
    Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
    Leuk Lymphoma. 2015;56:770-3.
    PubMed     Text format    


  446. YOSHIDA M, Tamagawa N, Nakao T, Kanashima H, et al
    Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
    Leuk Lymphoma. 2015;56:768-9.
    PubMed     Text format    


  447. ESTEPHAN F, Rogers HJ, Visconte V, Tabarroki A, et al
    Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.
    Leuk Lymphoma. 2015;56:811-3.
    PubMed     Text format    


  448. JAMROZIAK K, Szemraj J, Robak T, Tukiendorf A, et al
    Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
    Leuk Lymphoma. 2015;56:808-10.
    PubMed     Text format    


  449. POON ML, Fox PS, Samuels BI, O'Brien S, et al
    Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
    Leuk Lymphoma. 2015;56:711-5.
    PubMed     Text format     Abstract available


  450. MULAY S, Boruchov A
    Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Leuk Lymphoma. 2015;56:805-7.
    PubMed     Text format    


  451. GE Y, Yang B, Xu X, Dai Q, et al
    Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Leuk Lymphoma. 2015;56:730-8.
    PubMed     Text format     Abstract available


  452. KRUMBHOLZ M, Jung R, Bradtke J, Reinhardt D, et al
    Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene.
    Leuk Lymphoma. 2015;56:793-6.
    PubMed     Text format    


  453. MANT S, Taylor G, Dutton D, Butler A, et al
    Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases.
    Leuk Lymphoma. 2015;56:774-8.
    PubMed     Text format    


  454. UEDA M, Xie H, Sandhu RK, Walter RB, et al
    Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia.
    Leuk Lymphoma. 2015;56:782-4.
    PubMed     Text format    


  455. TAM CS, Stilgenbauer S
    How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Leuk Lymphoma. 2015;56:587-93.
    PubMed     Text format     Abstract available


  456. SCHMIDT C, Fingerle-Rowson G, Boehme A, Brendel K, et al
    Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
    Leuk Lymphoma. 2015;56:694-702.
    PubMed     Text format     Abstract available


  457. KU M, Wall M, MacKinnon RN, Walkley CR, et al
    Src family kinases and their role in hematological malignancies.
    Leuk Lymphoma. 2015;56:577-86.
    PubMed     Text format     Abstract available


  458. KHOURY HJ, Bixby DL
    Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Leuk Lymphoma. 2015;56:568-76.
    PubMed     Text format     Abstract available


  459. PLESA A, Elhamri M, Clapisson G, Mattei E, et al
    Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.
    Leuk Lymphoma. 2015;56:622-9.
    PubMed     Text format     Abstract available


  460. PARASOLE R, Petruzziello F, Messina C, Barisone E, et al
    Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Leuk Lymphoma. 2015;56:650-5.
    PubMed     Text format     Abstract available


  461. LICKLITER JD, Taylor K, Szer J, Grigg A, et al
    An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
    Leuk Lymphoma. 2015;56:630-8.
    PubMed     Text format     Abstract available


  462. GLITZA IC, Lu G, Shah R, Bashir Q, et al
    Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
    Leuk Lymphoma. 2015;56:602-7.
    PubMed     Text format     Abstract available


    February 2015
  463. REISS J, Link B, Ruan J, Furman R, et al
    Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    November 2014
  464. GIULINO-ROTH L
    EZH2: A potential new target in T-cell lymphoma?
    Leuk Lymphoma. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: